Project no.: HIV-NAT 003.1
Study Objectives:
- To explore the antiretroviral efficacy and tolerability of therapy with d4T/ddI in patients pretreated with AZT/3TC and therapy with d4T/3TC/Abacavir in patients pretreated with AZT/3TC/ddI for at least 48 weeks
- To access whether the switching of combination antiretroviral therapy before treatment failure is apparent (immediate switching) results in better virological and/or immunological responses then switching once treatment failure has become apparent (delayed switching)
- To explore the degree and duration of antiretroviral activity of double amd triple nucleoside combinations of AZT/3TC and AZT/3TC/ddI
Study Design:
- 101 patients entered this study
- 7 patients were failing therapy at the commencement of study and were switched immediately from AZT/3TC to d4T/ddI or from AZT/3TC/ddI to d4T/3TC/Abacavir
- The remaining 97 patients were re-randomized as follow:
- Immediate or deferred switching from AZT/3TC to d4T/ddI
- Immediate or deferred switching from AZT/3TC/ddI to d4T/3TC/Abacavir
Result: Pending